John J Lepore1, Eric Olson2, Laura Demopoulos2, Thomas Haws3, Zixing Fang4, April M Barbour5, Michael Fossler5, Victor G Davila-Roman6, Stuart D Russell7, Robert J Gropler8. 1. Metabolic Pathways and Cardiovascular Therapeutic Area Unit, GlaxoSmithKline, King of Prussia, Pennsylvania. Electronic address: john.j.lepore@gsk.com. 2. Metabolic Pathways and Cardiovascular Therapeutic Area Unit, GlaxoSmithKline, King of Prussia, Pennsylvania. 3. Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, King of Prussia, Pennsylvania. 4. Quantitative Sciences, Clinical Statistics, GlaxoSmithKline, King of Prussia, Pennsylvania. 5. Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania. 6. Cardiovascular Imaging and Clinical Research Core Laboratory, Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri. 7. Division of Cardiology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland. 8. Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri.
Abstract
OBJECTIVES: This study sought to determine if glucagon-like peptide (GLP)-1 ameliorates myocardial metabolic abnormalities in chronic heart failure. BACKGROUND:Albiglutide (GSK716155) is a GLP-1 agonist indicated for type 2 diabetes. METHODS: We performed a randomized, placebo-controlled study evaluating 12 weeks of albiglutide in New York Heart Association II or III subjects with ejection fraction <40%. Subjects received weekly placebo (n = 30) or albiglutide 3.75 mg (n = 12), 15 mg (n = 13), or 30 mg (n = 27). The primary comparison was between albiglutide 30 mg and placebo. Assessments included echocardiography, 6-minute-walk test, and peak oxygen consumption. In a subgroup of patients, myocardial glucose and oxygen use were assessed. Endpoints are reported as change from baseline ± SE. RESULTS: Albiglutide 30 mg compared with placebo did not improve change from baseline in left ventricular ejection fraction (2.4% [1.1%] vs. 4.4% [1.1%]; p = 0.22), 6-min walk test (18 [12] m vs. 9 [11] m; p = 0.58), myocardial glucose use (p = 0.59), or oxygen use (p = 0.25). In contrast, albiglutide 30 mg versus placebo improved change from baseline in peak oxygen consumption (0.9 [0.5] ml/kg/min vs. -0.6 [0.5] ml/kg/min; p = 0.02). Albiglutide was well tolerated. CONCLUSIONS: Although there was no detectable effect of albiglutide on cardiac function or myocardial glucose use, there was a modest increase in peak oxygen consumption, which could have been mediated by noncardiac effects. (A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure; NCT01357850).
RCT Entities:
OBJECTIVES: This study sought to determine if glucagon-like peptide (GLP)-1 ameliorates myocardial metabolic abnormalities in chronic heart failure. BACKGROUND: Albiglutide (GSK716155) is a GLP-1 agonist indicated for type 2 diabetes. METHODS: We performed a randomized, placebo-controlled study evaluating 12 weeks of albiglutide in New York Heart Association II or III subjects with ejection fraction <40%. Subjects received weekly placebo (n = 30) or albiglutide 3.75 mg (n = 12), 15 mg (n = 13), or 30 mg (n = 27). The primary comparison was between albiglutide 30 mg and placebo. Assessments included echocardiography, 6-minute-walk test, and peak oxygen consumption. In a subgroup of patients, myocardial glucose and oxygen use were assessed. Endpoints are reported as change from baseline ± SE. RESULTS: Albiglutide 30 mg compared with placebo did not improve change from baseline in left ventricular ejection fraction (2.4% [1.1%] vs. 4.4% [1.1%]; p = 0.22), 6-min walk test (18 [12] m vs. 9 [11] m; p = 0.58), myocardial glucose use (p = 0.59), or oxygen use (p = 0.25). In contrast, albiglutide 30 mg versus placebo improved change from baseline in peak oxygen consumption (0.9 [0.5] ml/kg/min vs. -0.6 [0.5] ml/kg/min; p = 0.02). Albiglutide was well tolerated. CONCLUSIONS: Although there was no detectable effect of albiglutide on cardiac function or myocardial glucose use, there was a modest increase in peak oxygen consumption, which could have been mediated by noncardiac effects. (A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure; NCT01357850).
Authors: Roni Nielsen; Anders Jorsal; Peter Iversen; Lars Poulsen Tolbod; Kirsten Bouchelouche; Jens Sørensen; Hendrik Johannes Harms; Allan Flyvbjerg; Lise Tarnow; Caroline Kistorp; Ida Gustafsson; Hans Erik Bøtker; Henrik Wiggers Journal: J Nucl Cardiol Date: 2017-08-02 Impact factor: 5.952
Authors: Benjamin W Van Tassell; Justin Canada; Salvatore Carbone; Cory Trankle; Leo Buckley; Claudia Oddi Erdle; Nayef A Abouzaki; Dave Dixon; Dinesh Kadariya; Sanah Christopher; Aaron Schatz; Jessica Regan; Michele Viscusi; Marco Del Buono; Ryan Melchior; Pranav Mankad; Juan Lu; Robin Sculthorpe; Giuseppe Biondi-Zoccai; Edward Lesnefsky; Ross Arena; Antonio Abbate Journal: Circ Heart Fail Date: 2017-11 Impact factor: 8.790
Authors: T Dung Nguyen; Yasushige Shingu; Paulo A Amorim; Christina Schenkl; Michael Schwarzer; Torsten Doenst Journal: J Cardiovasc Transl Res Date: 2018-02-20 Impact factor: 4.132
Authors: Kieren J Mather; Robert V Considine; LaTonya Hamilton; Niral A Patel; Carla Mathias; Wendy Territo; Adam G Goodwill; Johnathan D Tune; Mark A Green; Gary D Hutchins Journal: J Clin Endocrinol Metab Date: 2018-09-01 Impact factor: 5.958